India Pharma Outlook Team | Friday, 10 October 2025
Chris Preti, CEO of CDMO Sterile Injectables, announced on Friday that Jubilant HollisterStier LLC, a division of Jubilant Pharmova Ltd., will invest USD 300 million by FY28 in the US to double its sterile injectable manufacturing capacity, with President Donald Trump's tariffs speeding up its initial plans.At a USD 132 million investment, the company opened its third sterile fill and finish line at its Spokane manufacturing facility in Washington.
"Our overall investment is almost USD 300 million at our Spokane facility. This is the first of the two phases ... This USD 132 million is phase one, which is our third line," he said.Preti further said, "This will bring an additional 50 per cent of capacity in the US that is available now and then, the additional investment, totaling USD 300 million in all, will be actually completed by the end of fiscal year 2028 which will bring on another 50 per cent of additional capacity."
On the company's current capacity, he said, "Today, we produce approximately 50 million units of vials annually. In the future, when we're done with both of these expansions, we'll be actually producing approximately 100 million vials annually."
